[{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Palmitil","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder for Inhalation in Capsule","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Insmed \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Treprostinil Palmitil

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : INS1009 (treprostinil palmitil) inhalation powder is a dry powder formulation of treprostinil palmitil, which being evaluated for the treatment of patients with PAH.

                          Brand Name : INS1009

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 19, 2021

                          Lead Product(s) : Treprostinil Palmitil

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank